Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study

Therapeutic Drug Monitoring

Volumn 22, Issue 3, 2000, Pages 295-301

  Iacona, Isabella ^a   Lazzarino, Mario ^a   Avanzini, Maria Antonietta ^a   Rupolo, Maurizio ^b   Arcaini, Luca ^a   Astori, Cesare ^a   Lunghi, Francesca ^a   Orlandi, Ester ^a   Morra, Enrica ^c   Zagonel, Vittorina ^b   Regazzi, Mario B ^a,d  

^a UNIVERSITY OF PAVIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

CD20 antigen; ELISA; Follicular NHL; Pharmacokinetics; Rituximab

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ACCURACY; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLICULAR LYMPHOMA; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY FLUID COMPARTMENTS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, FOLLICULAR; PREDNISONE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VINCRISTINE;

EID: 0034090042     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200006000-00010     Document Type: Article

References (15)

1. Liu AY, Robinson RR, Murray EJ, et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987;139:3521-3526.
2. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 1989;386:4220-4224.
3. Reff M, Carner K, Chambers K, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
4. Stashenko P, Nadler L, Hardy R, et al. Characterization of a human B-lymphocytes specific antigen. J Immunol 1980;125:1678-1685
5. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993;121: 1121-1132
6. Einfeld D, Braun J, Valentine M, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-717.
7. Press O, Appelbaum F, Ledbetter J, et al. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 1987; 69:584-591.
8. Maloney D, Liles T, Czerwinski D, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466.
9. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195.
10. McLaughlin P, Grillo-López AJ, Link B, et al. Rituximab chimeric anti CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program. J Clin Oncol 1998;16:2825-2833.
11. Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliterative disorders evaluation of response on 48 patients. Eur J Haematol 1999;62:76-82.
12. Piro LD, White CA, Grillo-López AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-661.
13. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of chimeric anti-CD20 monoclonal anti-body (IDEC-C2B8, Rituximab) in relapsed B-cell lymphoma. Ann Oncol 1998;9:527-534.
14. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
15. Shah VP, Midha KK, Digne S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309-312.